Novo Nordisk
$59.249876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$59.24
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$2.51 (+4.42%) As of 10:12 AM EDT today
+$2.51 (+4.42%) Today
Why Robinhood?
You can buy or sell Novo Nordisk and other stocks, options, ETFs, and crypto commission-free!
About NVO
Novo-Nordisk A/S, also called Novo Nordisk, is a healthcare company, which engages in the research, development, manufacture, and marketing of pharmaceutical products. It operates through the following segments: Diabetes & Obesity Care, and Biopharmaceuticals. Read More The Diabetes & Obesity Care segment covers products for insulin; GLP-1 and related delivery systems; oral antidiabetic products; and obesity. The Biopharmaceuticals segment offers products for haemophilia; growth hormone therapy; and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.
Employees
43,258
Headquarters
Bagsværd, Capital Region
Founded
1925
Market Cap
96.21B
Price-Earnings Ratio
23.07
Dividend Yield
1.55
Average Volume
3.38M
High Today
$59.53
Low Today
$58.78
Open Price
$58.78
Volume
855.79K
52 Week High
$64.82
52 Week Low
$46.47
Collections
NVO News
Analyst Ratings
54%
of 28 ratings
Buy
54%
Hold
29%
Sell
18%
NVO Earnings
$0.00
$0.23
$0.45
$0.68
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Q1 2020
Estimated
— per share
Actual
Available May 6, Pre-Market